New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 18, 2013
13:21 EDTYUM, BCRX, GSK, ZNH, CEABird-flu may add risks to China slowdown, Bloomberg says
China’s bird-flu outbreak is affecting businesses from restaurants to travel, according to Bloomberg, citing a note to investors this week from Goldman Sachs that said the outbreak “may suppress domestic consumption in the near term." Bloomberg outlined the potential on a number of publicly-traded companies, including Yum! Brands (YUM), China Southern Airlines (ZNH) and China Eastern Airlines (CEA). The Fly notes companies developing bird flu vaccines include BioCryst (BCRX) and Glaxo (GSK). Reference Link
News For YUM;BCRX;GSK;ZNH;CEA From The Last 14 Days
Check below for free stories on YUM;BCRX;GSK;ZNH;CEA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 18, 2014
13:47 EDTYUMPizza Hut opens first restaurant in Africa, plans to open dozens more
Subscribe for More Information
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.
07:52 EDTYUMPizza Hut testing 30% lower calorie pie, USA Today reports
Subscribe for More Information
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
September 16, 2014
07:33 EDTGSKMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTGSKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
17:35 EDTYUMChurchill Downs, Yum! Brands extend five-year Kentucky Derby agreement
Subscribe for More Information
16:10 EDTGSKFive Prime announces option exercise by GlaxoSmithKline to obtain license
Subscribe for More Information
07:27 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
06:11 EDTYUMYum! Brands looking beyond pizza, tacos to Banh concept, USA Today reports
Subscribe for More Information
September 10, 2014
16:15 EDTYUMYum! Brands increases quarterly dividend 11% to 41c from 37c
Subscribe for More Information
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
September 9, 2014
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
September 8, 2014
08:48 EDTGSKGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
September 7, 2014
13:57 EDTGSKGlaxoSmithKline Ebola vaccine works in tests on monkeys, Bloomberg says
Subscribe for More Information
12:42 EDTBCRXBioCryst announces RAPIVAB trial results for the treatment of influenza
Subscribe for More Information
September 5, 2014
10:57 EDTBCRXBioCryst falls after WHO posts document on potential Ebola therapies
Shares of BioCryst Pharmaceuticals (BCRX) are sliding in early trading after the World Health Organization posted documents ahead of a meeting it is holding to discuss the recent Ebola outbreak and potential strategies to combat the disease. WHAT'S NEW: This week, on September 4-5, WHO is bringing together technical experts from the groups developing Ebola interventions along with people working to overcome Ebola virus disease, the group stated on its website. WHAT'S NOTABLE: In a background document on potential Ebola therapies and vaccines, WHO wrote regarding the availability and feasibility of BCX4430 from Biocryst that the drug "needs animal treatment and protection data for EVD before it can be considered. No material is currently available for field use." PRICE ACTION: Shares of BioCryst are down 50c, or 3.76%, to $12.28. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use